The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review

Background and Purpose:& nbsp;Pancreatic islet autoantibodies (iAb) are the hallmark of autoimmunity in type 1 diabetes. A more comprehensive understanding of the global iAb prevalence could help reduce avertible morbidity and mortality among children and adolescents and contribute to the understanding in the observed differences in the incidence, prevalence and health outcomes of children and adolescents with type 1 diabetes across and within countries. We present the first scoping review that provides a global synthesis of the prevalence of iAb in children and adolescents with type 1 diabetes.Research Design and Methods:& nbsp;We searched Ovid MEDLINE(R) with Daily Update, Embase (Elsevier, embase.com) and PubMed (National Library of Medicine -NCBI), for studies pertaining to prevalence in children and adolescents (0-19) with type 1 diabetes published between 1 Jan 1990 and 18 June 2021. Results were synthesized using Covidence systematic review software and meta-analysis was completed using R v3 & BULL;6 & BULL;1. Two reviewers independently screened abstracts with a third reviewer resolving conflicts (k= 0 & BULL;92).Results:& nbsp;The review revealed 125 studies from 48 different countries, with 92 from high-income countries. Globally, in new-onset type 1 diabetes, IA-2A was the most prevalent iAb 0 & BULL;714 [95% CI (0 & BULL;71, 0 & BULL;72)], followed by ICA 0 & BULL;681 [95% CI (0 & BULL;67, 0 & BULL;69)], ZnT8A was 0 & BULL;654 [95% CI (0 & BULL;64, 0 & BULL;66)], GADA 0 & BULL;636 [95% CI (0 & BULL;63, 0 & BULL;66)] and then IAA 0 & BULL;424 [95% CI (0 & BULL;42, 0 & BULL;43)], with substantial variation across world regions. The weighted mean prevalence of IA-2A was more variable, highest in Europe at 0 & BULL;749 [95% CI (0 & BULL;74, 0 & BULL;76)] followed by Northern America 0 & BULL;662 [95% CI (0 & BULL;64, 0 & BULL;69)], Latin America and the Caribbean 0 & BULL;632 [95% CI (0 & BULL;54, 0 & BULL;72)], Oceania 0 & BULL;603 [95% CI (0 & BULL;54, 0 & BULL;67)], Asia 0 & BULL;466 [95% CI (0 & BULL;44, 0 & BULL;50)] and Africa 0 & BULL;311 [95% CI (0 & BULL;23, 0 & BULL;40)]. In established cases of type 1 diabetes, GADA was the most prevalent iAb 0 & BULL;407 [95% CI (0 & BULL;39, 0 & BULL;42)] followed by ZnT8A 0 & BULL;322 [95% CI (0 & BULL;29, 0 & BULL;36)], IA-2A 0 & BULL;302 [95% CI (0 & BULL;29, 0 & BULL;32)], IAA 0 & BULL;258 [95% CI (0 & BULL;24, 0 & BULL;26)] and ICA 0 & BULL;145 [95% CI (0 & BULL;13, 0 & BULL;16)], again with substantial variation across world regions.Conclusion:& nbsp;Understanding the global prevalence of iAb in children and adolescents with type 1 diabetes could help with earlier identification of those at-risk of developing type 1 diabetes and inform clinical practice, health policies, resource allocation, and targeted healthcare interventions to better screen, diagnose and manage children and adolescents with type 1 diabetes

Automated summary

This study provides a global synthesis of the prevalence of iAb in children and adolescents with type 1 diabetes from different countries and regions, revealing IA-2A as the most prevalent in new-onset diabetes and GADA as the most common in established cases. There are substantial variations in prevalence across different regions.